Spots Global Cancer Trial Database for Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
Official Title: Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
Study ID: NCT01768195
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.
Detailed Description: HBsAg Positive lymphoma patients are treated with entecavir when they receive rituximab-based immunochemotherapy. Entecavir 0.5mg daily is administrated from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking University Cancer Hospital & Institute, Beijing, Beijing, China
307 Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China
309 Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China
Aerospace Central Hospital, Beijing, Beijing, China
Air Force General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China
Beijing Hospital, Beijing, Beijing, China
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
First Hospital affiliated to General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China
General Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University First Hospital, Beijing, Beijing, China
Peking University People's Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijing, Beijing, China
Contact Details
Name: Jun Zhu
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
